37
Participants
Start Date
July 31, 2009
Primary Completion Date
December 31, 2013
Study Completion Date
June 30, 2014
temsirolimus
Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
RECRUITING
Charité Campus Benjamin Franklin, Berlin
NOT_YET_RECRUITING
Hematology, Klinikum Frankfurt/Oder, Frankfurt (Oder)
RECRUITING
Neurology, Knappschaftskrankenhaus Bochum, Bochum University, Bochum
RECRUITING
Neurology, University Hospital Bonn, Bonn
NOT_YET_RECRUITING
Hematology, University Hospital Heidelberg, Heidelberg
RECRUITING
Klinikum Grosshadern, University Hospital Munich, Munich
Collaborators (1)
Pfizer
INDUSTRY
Charite University, Berlin, Germany
OTHER